Ilan Richter

Dr. Ilan Richter

Rabin Medical Center, Petah Tikva, Israel
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2021 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
GWGuy Witberg
Guy Witberg
NBNoam Barda
Noam Barda
SHSara Hoss
Sara Hoss
IRIlan Richter
Ilan Richter
MWMaya Wiessman
Maya Wiessman
RKRan Kornowski
Ran Kornowski
Reports have suggested an association between the development of myocarditis and the receipt of messenger RNA (mRNA) vaccines against coronavirus disease 2019 (Covid-19), but the frequency and severity of myocarditis after vaccination have not been extensively explored. We searched the database of Clalit Health Services, the largest health care organization (HCO) in Israel, for diagnoses of myocarditis in patients who had received at least one dose of the BNT162b2 mRNA vaccine (Pfizer–BioNTech). The diagnosis of myocarditis was adjudicated by cardiologists using the case definition used by the Centers for Disease Control and Prevention. We abstracted the presentation, clinical course, and outcome from the patient’s electronic health record. We performed a Kaplan–Meier analysis of the incidence of myocarditis up to 42 days after the first vaccine dose. Among more than 2.5 million vaccinated HCO members who were 16 years of age or older, 54 cases met the criteria for myocarditis. The estimated incidence per 100,000 persons who had received at least one dose of vaccine was 2.13 cases (95% confidence interval [CI], 1.56 to 2.70). The highest incidence of myocarditis (10.69 cases per 100,000 persons; 95% CI, 6.93 to 14.46) was reported in male patients between the ages of 16 and 29 years. A total of 76% of cases of myocarditis were described as mild and 22% as intermediate; 1 case was associated with cardiogenic shock. After a median follow-up of 83 days after the onset of myocarditis, 1 patient had been readmitted to the hospital, and 1 had died of an unknown cause after discharge. Of 14 patients who had left ventricular dysfunction on echocardiography during admission, 10 still had such dysfunction at the time of hospital discharge. Of these patients, 5 underwent subsequent testing that revealed normal heart function. Among patients in a large Israeli health care system who had received at least one dose of the BNT162b2 mRNA vaccine, the estimated incidence of myocarditis was 2.13 cases per 100,000 persons; the highest incidence was among male patients between the ages of 16 and 29 years. Most cases of myocarditis were mild or moderate in severity. (Funded by the Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute.)

20 June 2022 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
GWGuy Witberg
Guy Witberg
ULUri Landes
Uri Landes
YTYeela Talmor-Barkan
Yeela Talmor-Barkan
IRIlan Richter
Ilan Richter
MBMarco Barbanti
Marco Barbanti
RKRan Kornowski
Ran Kornowski

19 October 2022 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
GWGuy Witberg
Guy Witberg
OMOri Magen
Ori Magen
SHSara Hoss
Sara Hoss
YTYeela Talmor-Barkan
Yeela Talmor-Barkan
IRIlan Richter
Ilan Richter
RKRan Kornowski
Ran Kornowski
We previously reported that the incidence of myocarditis in Israel after receipt of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) against coronavirus disease 2019 (Covid-19) was highest among males between the ages of 16 and 29 years (10.7 cases per 100,000 persons).1 BNT162b2 vaccination has since been approved for adolescents between the ages of 12 and 15 years, and initial evidence from this age group in Israel suggests a similar incidence and mild course of myocarditis, although follow-up was limited to 30 days.2 A study from Hong Kong showed an incidence of 28.7 cases per 100,000 persons, but cases were not adjudicated beyond the discharge diagnosis code of the International Classification of Diseases, Ninth Revision (ICD-9).3 Our aim was to provide further evidence regarding the incidence of myocarditis after vaccination among adolescents and data regarding follow-up of 6 months or more.

13 May 2025 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
AVAndrea Fernandez Valledor
Andrea Fernandez Valledor
CMCathrine M. Moeller
Cathrine M. Moeller
DODaniel Oren
Daniel Oren
JBJulia Baranowska
Julia Baranowska
SRSalwa Rahman
Salwa Rahman
NUNir Uriel
Nir Uriel

20 March 2023 in Andrology
Verified
Journal Article
Closed access
YRYaron Rudman
Yaron Rudman
HDHadar Duskin‐Bitan
Hadar Duskin‐Bitan
IRIlan Richter
Ilan Richter
GTGloria Tsvetov
Gloria Tsvetov
HMHiba Masri‐Iraqi
Hiba Masri‐Iraqi
ISIlan Shimon
Ilan Shimon

26 March 2025 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
IRIlan Richter
Ilan Richter
JFJustin Fried
Justin Fried
KCKevin Clerkin
Kevin Clerkin
JRJayant Raikhelkar
Jayant Raikhelkar
DLDor Lotan
Dor Lotan
NUNir Uriel
Nir Uriel